Claims
- 1. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising a steroid compound.
- 2. The method of claim 1, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 3. The method of claim 1, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 4. The method of claim 1, wherein said steroid compound is a progestin compound.
- 5. The method of claim 4, wherein said progestin compound is selected from the group consisting of (17α)-17-Hydroxy-19-norpregn-4-en-20-yn-3-one and 17a-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione.
- 6. The method of claim 1, wherein said steroid is an anti-inflammatory steroid.
- 7. The method of claim 6, wherein said anti-inflammatory steroid is flunisolide.
- 8. The method of claim 1, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 9. The method of claim 8, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease.
- 10. The method of claim 1, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 11. The method of claim 10, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 12. The method of claim 1, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 13. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising an anti-motion sickness agent.
- 14. The method of claim 13, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 15. The method of claim 13, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 16. The method of claim 13, wherein said anti-motion sickness agent is a HI histamine receptor blocker compound.
- 17. The method of claim 16, wherein said H1 histamine receptor blocker compound is 1-[(4-Chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine.
- 18. The method of claim 13, wherein said anti-motion sickness agent is a belladonna alkaloid.
- 19. The method of claim 18, wherein said belladonna alkaloid is 6β,7β-epoxy-1αH,5αH-tropan-3α-ol(−)-tropate.
- 20. The method of claim 13, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 21. The method of claim 20, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 22. The method of claim 13, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 23. The method of claim 22, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 24. The method of claim 13, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 25. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising an antibiotic compound at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 26. The method of claim 25, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 27. The method of claim 25, wherein said antibiotic compound is a macrolide antibiotic compound.
- 28. The method of claim 27, wherein said macrolide antibiotic compound is selected from the group consisting of erythromycin, troleandomycin, azithromycin and clarithromycin
- 29. The method of claim 25, wherein said antibiotic compound is a tetracycline compound or derivative.
- 30. The method of claim 29, wherein said tetracycline derivative compound is selected from the group consisting of chlorotetracycline, oxytetracycline, demeclocycline, methacycline. doxycycline and minocycline.
- 31. The method of claim 25, wherein said antibiotic is a tobramycin compound or a sulfacetamide compound.
- 32. The method of claim 25, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 33. The method of claim 32, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease.
- 34. The method of claim 25, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 35. The method of claim 34, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 36. The method of claim 25, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 37. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising a calcium channel blocker compound.
- 38. The method of claim 37, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 39. The method of claim 37, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 40. The method of claim 37, wherein said calcium channel blocker compound is selected from the group consisting of isopropyl (2-methoxyethyl) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylate; α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-α-1(1-methylethyl)benzeneacetonitrile, 3,5-pyridinedicarboxylic acid; 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester and 1,8-dihydroxy-9(10H)-anthracenone.
- 41. The method of claim 37, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 42. The method of claim 41, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 43. The method of claim 37, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 44. The method of claim 43, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 45. The method of claim 37, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 46. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising an anti-depressant compound.
- 47. The method of claim 46, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 48. The method of claim 46, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 49. The method of claim 46, wherein said anti-depressant compound is selected from the group consisting of lithium carbonate, trazodone, bupropion hydrochloride, fluoxetine hydrocloride and sertraline hydrochloride.
- 50. The method of claim 46, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 51. The method of claim 50, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 52. The method of claim 46, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 53. The method of claim 52, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 54. The method of claim 46, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 55. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising an alkali metal compound.
- 56. The method of claim 55, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 57. The method of claim 55, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 58. The method of claim 55, wherein said alkali metal compound is selected from the group consisting of lithium, caesium, rubidium and francium.
- 59. The method of claim 55, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 60. The method of claim 59, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 61. The method of claim 55, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 62. The method of claim 61, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 63. The method of claim 55, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 64. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising an anti-arrhythmic agent.
- 65. The method of claim 64, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 66. The method of claim 64, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 67. The method of claim 64, wherein said anti-arrhythmic agent is a beta-adrenergic receptor blocking compound.
- 68. The method of claim 67, wherein said beta-adrenergic receptor blocking compound is selected from the group consisting of d, 1-N-[4-[1-hydroxy-2[(methylethyl)amino]ethyl]phenyl]methane-sulfonamide monohydrochloride and (S)-1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-2-propanol (Z)-2-butenedioate
- 69. The method of claim 64, wherein said anti-arrhythmic agent is a sodium channel blocker compound.
- 70. The method of claim 69, wherein said sodium channel blocker compound is selected from the group consisting of lidocaine, mexiletine and prilocaine.
- 71. The method of claim 64, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 72. The method of claim 71, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 73. The method of claim 64, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 74. The method of claim 73, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 75. The method of claim 64, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 76. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising dietary supplement at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 77. The method of claim 76, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 78. The method of claim 76, wherein said dietary supplement compound is selected from the group consisting of yohimbine, zinc, β-carotene, docosahexaenoic acid and retinol acetate.
- 79. The method of claim 76, wherein said dietary supplement compound is a presynaptic alpha-adrenergic receptor blocking compound.
- 80. The method of claim 79, wherein said presynaptic alpha-adrenergic receptor blocking compound is selected from the group consisting of yohimbine, medetomidine hydrochloride and atipamezole.
- 81. The method of claim 76, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 82. The method of claim 81, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 83. The method of claim 76, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 84. The method of claim 83, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 85. The method of claim 76, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 86. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising muscle relaxant compound.
- 87. The method of claim 86, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 88. The method of claim 86, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 89. The method of claim 86, wherein said muscle relaxant compound is (Z)-5-fluoro-2-methyl-1-[[p-(methylsulfyl)phenyl]methylene]-1H-indene-3 acetic acid.
- 90. The method of claim 86, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 91. The method of claim 90, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 92. The method of claim 86, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 93. The method of claim 92, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 94. The method of claim 86, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 95. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising a dopaminergic agonist compound.
- 96. The method of claim 95, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 97. The method of claim 95, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 98. The method of claim 95, wherein said dopaminergic agonist compound is prolatin-inhibiting compound.
- 99. The method of claim 95, wherein said prolatin inhibiting compound is bromocriptine.
- 100. The method of claim 95, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 101. The method of claim 100, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 102. The method of claim 96, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 103. The method of claim 102, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 104. The method of claim 96, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 105. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising carbonic anhydrase inhibitor compound.
- 106. The method of claim 105, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 107. The method of claim 105, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 108. The method of claim 105, wherein said carbonic anhydrase inhibitor compound is selected from the group consisting of methazolamide, acetazolamide, dorzolamide and brinzolamide.
- 109. The method of claim 105, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 110. The method of claim 109, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 111. The method of claim 105, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 112. The method of claim 111, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 113. The method of claim 105, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 114. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising an anesthetic compound.
- 115. The method of claim 114, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 116. The method of claim 114, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 117. The method of claim 114, wherein said anesthetic compound is corticosteroid compound.
- 118. The method of claim 117, wherein said corticosteroid compound is selected from the group consisting of pramoxine, hydocortizone, hetamethazone, budesonide, prednisone and cortisone.
- 119. The method of claim 114, wherein said anesthetic is dyclonine hydrochoride.
- 120. The method of claim 114, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 121. The method of claim 120, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 122. The method of claim 114, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 123. The method of claim 122, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 124. The method of claim 114, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 125. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising an opioid antagonist compound.
- 126. The method of claim 125, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 127. The method of claim 125, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 128. The method of claim 125, wherein said opiod antagonist compound is selected from the group consisting naltrexone, propoxyphene and pentazocine.
- 129. The method of claim 125, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 130. The method of claim 129, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 131. The method of claim 125, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 132. The method of claim 131, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 133. The method of claim 125, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 134. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising a thiol compound.
- 135. The method of claim 134, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 136. The method of claim 134, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 137. The method of claim 134, wherein said thiol compound is selected from the group consisting 2-mercaptoethanesulfonic acid, propyl mercaptan, ethyl mercaptan and butyl mercaptan.
- 138. The method of claim 134, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 139. The method of claim 138, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 140. The method of claim 134, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 141. The method of claim 140, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 142. The method of claim 134, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
- 143. A method of inhibiting death of a neuronal cell in a mammal, comprising administering to said mammal a composition comprising a non-steroidal anti-inflammatory compound.
- 144. The method of claim 143, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced neuronal cell death.
- 145. The method of claim 143, wherein said composition is administered at a dose sufficient to inhibit apoptotic death of said neuronal cell.
- 146. The method of claim 143, wherein said non-steroidal anti-inflammatory compound is selected from the group consisting sulindac, ibuprofen, nabumentone, naproxen and acetaminophen.
- 147. The method of claim 143, wherein said mammal is suffering from or at risk of developing a neurodegenerative disorder.
- 148. The method of claim 147, wherein said neurodegenerative disorder is selected from the group consisting of Amyotrophic Lateral Sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease
- 149. The method of claim 143, wherein said mammal is suffering from or at risk of developing a neurological disorder.
- 150. The method of claim 149, wherein said neurological disorder is selected from the group consisting of diabetic neuropathy, cerebral hypoxia, encephalitis and menengitis.
- 151. The method of claim 143, wherein said mammal is at risk of experiencing a stroke or has suffered a stroke.
RELATED U.S. APPLICATION
[0001] This application claims priority to U.S. Ser. No. 60/262,720 filed Jan. 19, 2001, which is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60262720 |
Jan 2001 |
US |